FIMECS Presents IRAK-M Program for Immuno-Oncology at SITC 2019
News release Download PDF
Kanagawa, Japan, 26, October 2019 – FIMECS, Inc. (“FIMECS”) a private biotechnology company creating a new class of drugs based on targeted protein degradation, today announced research demonstrating drug discovery activity of the company’s first-in-class hetero-bifunctional molecules to specifically degrade IRAK-M protein. The data would be presented at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2019 in National Harbor, MD, U.S.A., November 6–10, 2019.
Title: “Targeted IRAK-M degradation as a novel approach in cancer-immunotherapy overcoming innate-driven immunosuppression”
Presenters: Kanae Gamo, Naomi Kitamoto, Tomoaki Hayashi, Yoshihide Tomata, Yusuke Tominari
Session category: Immune Cell Biology
Poster No.: P596
IRAK-M has an important role in tightly controlling innate immune responsiveness to preserve homeostasis, mediating immune tolerance, and acts as a negative feedback regulator of TLR/IL-1R signaling pathway. Targeting IRAK-M, which expression is restricted to myeloid cells, would be potentially limiting adverse events against non-target tissues. From supporting evidence for the role of IRAK-M in innate immunosuppressive capacity of tumor-associated macrophages (TAMs) or dendritic cells (DCs), we have developed compounds targeting IRAK-M as an effective cancer-immunotherapy strategy.
FIMECS discovered multiple drug candidates within a year by applying the company’s platform technology “RaPPIDS™. In the poster presentation, the company presents an update of IRAK-M degrader discovery for immuno-oncology.
About FIMECS, Inc.
FIMECS, Inc. is developing a new class of drugs based on targeted protein degradation for the currently ‘undruggable’ targets in immuno-oncology and oncology areas. The company became able to discover drug candidates for inducing the degradation of disease-relevant targeted proteins by integrating proprietary E3 ligase binders and RaPPIDS™ platform. This drug discovery platform will help providing drugs to the patients all over the world through various internal and collaboration projects.
RaPPIDS™ (Rapid Protein Proteolysis Inducer Discovery System) is one of the proprietary drug discovery platforms of FIMECS, Inc. used to generate therapeutic candidates of the targeted protein degrader. The platform allows synthesizing and evaluating various degraders quickly based on the company’s proprietary know-how and diversity-oriented synthesis, and delivery of the drug candidates with the best combination of target protein binders, linkers, and E3 ligase binders.
# # #
FIMECS, Inc. Media and Investor Contact:
CFO and VP of Corporate Development